Risk of hepatitis C reinfection among people with current injecting drug use following successful HCV treatment

成功治疗丙型肝炎后目前注射吸毒者再​​次感染丙型肝炎的风险

• 批准号: nhmrc : 1128886
• 负责人: A/Pr Gail Matthews
• 金额: $ 153.45万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/risk-hepatitis-c-hcv-treatment/948289
• 关键词: Risk; hepatitis; reinfection; among; people

In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.

在澳大利亚，丙型肝炎（HCV）相关的发病率和死亡率正在上升。最近临床医学最重要的突破之一是批准了安全、简单、无干扰素的HCV治疗，治愈率达95%。虽然注射毒品的人占新的和现有的HCV病例的大多数，但治疗后可能会发生再感染。该项目赠款的目标是检查注射毒品者成功治疗后的HCV治疗和再感染。